Dan Swisher: And then, on the ex-U.S. growth for Epidiolex, we do see strong continued growth for 2023 and contributing towards 2025. Importantly, we had some headwinds that we don’t think we’ll face as directly in terms of FX rates. And importantly, now, we’ve got approval towards the end of last year in France with full reimbursement, so we’re now fully launched in all five major European countries and we’ve still got some smaller markets to add over time. So, we’re approved in 15 of 30 — we’re launched in 15 of 35 approved markets. And then, more from a medium-term perspective, we see significant opportunity in the Asia Pac region, and in particular Japan, where we’ve got a Phase 3 study ongoing and we look forward to thinking through our commercialization strategies there for the Neuroscience portfolio.
Renee Gala: And then, maybe just jumping in on corporate development, in terms of areas we’re interested in, clearly, we’re definitely focusing on neuro and oncology, but we’re also looking more broadly at rare and orphan in general. This is a space that we’re very comfortable in currently within our neuroscience and oncology therapeutic areas. But as we’re looking at corporate development opportunities, we’ve tended to be technology-agnostic, meaning between small molecule, large molecule, botanicals. And as we continue to build and enhance our commercial capabilities, Bruce had mentioned earlier, the strong focus on patient need, when you can have a meaningful impact for patients to be able to apply our insights, it gives us confidence in looking at multiple types of molecules and potentially extending beyond neuro and oncology.
But the primary focus is still in our neuroscience and oncology therapeutic areas. In terms of the stage of compounds, we’re looking at commercial, near commercial, but also pipeline deals. You’ve heard us talk about our guidance today. We’re investing heavily there, and we do think our increased capabilities that we’ve developed both organically but also with the acquisition of GW has set us up really well.
Operator: Thank you. Our last question comes from Greg Fraser with Truist. Your line is open.
Greg Fraser: Great. Thanks for squeezing me in. On Xywav, you’re clearly confident in continued strong growth for both indications. On narcolepsy, do you expect the pace of new patient adds to potentially slow a bit this year, given the oxybate market dynamics? Last year, I think you added about 500 new patients each quarter. Curious whether you think that pace can continue with the various moving parts in the oxybate market this year. Thank you so much.
Bruce Cozadd: Kim, anything you want to add on narcolepsy adds in ’23?
Kim Sablich: Yes. Just that we’re still confident here that we’ve got clear differentiation based on the reduced sodium and that we’re going to continue at a nice pace, both in terms of patient conversions as well as new patient starts where we’re already seeing the vast majority of patients being started on Xywav versus Xyrem. So, overall, we feel really good about that momentum continuing throughout the year.
Operator: Thank you. There are no further questions. I’d like to turn the call back over to Bruce for any closing remarks.
Bruce Cozadd: All right. Thank you, Operator. And I just — I want to close by recognizing the passion and innovation of our 2,800 talented employees around the globe who come to work each day, dedicating to improving the lives of more patients than before. And I also want to thank our partners and our shareholders for their continued confidence and support. Thanks, everyone, for joining us today and stay well.
Operator: Thank you for your participation. You may now disconnect. Everyone, have a great day.
